Aims: 1) To assess acceptability and feasibility of ASICA 2) to evaluate
ASICA in a randomized controlled trial.
Methods: Interviews with 21 people previously treated for cutaneous melanoma and pilot-testing with 20 people treated for melanoma. 240 people with primary cutaneous melanoma were randomized to ASICA or treatment as usual. Participants were followed up by postal questionnaire at 2, 6 and 12 months following randomization on the following measures: TSSE practice, intentions, self-efficacy and planning; Melanoma Worry Scale; the Hospital Anxiety and Depression Scale (HADs); the EuroQoL EQ-5D-5L.
Results: 1) Interviewees were positive about the use of technology to remind and instruct on TSSE, conducting it in their homes and getting feedback quickly. Pilot participants were strongly positive; intention and self-efficacy increased, 15 adhered well to the intervention, 4 intermittently and one withdrew. 2) Trial results will be reported
Conclusions: The ASICA intervention was acceptable to most patients and feasible following small technical adjustments. Results of the randomized controlled trial will inform future use of ASICA.